[3H]4-(dimethylamino)-N-(4-(4-(2-methoxyphenyl)piperazin-1-yl)- butyl)benzamide: A selective radioligand for dopamine D3 receptors. II. Quantitative analysis of dopamine D3 and D2 receptor density ratio in the caudate-putamen

Synapse

Volumn 64, Issue 6, 2010, Pages 449-459

  Xu, Jinbin ^a   Hassanzadeh, Babak ^a   Chu, Wenhua ^a   Tu, Zhude ^a   Jones, Lynne A ^a   Luedtke, Robert R ^b   Perlmutter, Joel S ^a   Mintun, Mark A ^a   Mach, Robert H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

DA D3 D2 receptors; Dopamine; Quantitative autoradiography

Indexed keywords

[3 H]4 (DIMETHYLAMINO) N [4 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]BUTYL]BENZAMIDE; BENZAMIDE DERIVATIVE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; RACLOPRIDE; TRITIUM; UNCLASSIFIED DRUG; DOPAMINE RECEPTOR BLOCKING AGENT; PIPERAZINE DERIVATIVE; WC10 COMPOUND;

ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; BRAIN; CAUDATE NUCLEUS; IN VITRO STUDY; MATHEMATICAL MODEL; NONHUMAN; PRIORITY JOURNAL; PUTAMEN; RAT; RECEPTOR BINDING; RHESUS MONKEY; SPRAGUE DAWLEY RAT; ANIMAL; BINDING COMPETITION; CELL CULTURE; CELL LINE; DRUG EFFECT; MACACA; MALE; MATHEMATICAL PHENOMENA; METABOLISM; METHODOLOGY; PHYSIOLOGY; RADIOASSAY; THEORETICAL MODEL;

ANIMALS; AUTORADIOGRAPHY; BINDING, COMPETITIVE; CAUDATE NUCLEUS; CELL LINE; CELLS, CULTURED; DOPAMINE ANTAGONISTS; MACACA MULATTA; MALE; MATHEMATICAL CONCEPTS; MODELS, THEORETICAL; PIPERAZINES; PUTAMEN; RACLOPRIDE; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3;

EID: 77952893920     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20748     Document Type: Article

References (53)

1. 2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 97:8104-8109.
2. 3 subtypes. Brain Res 649:95-110.
3. 3 dopamine receptor: Pharmacologic properties and development of antibodies. J Pharmacol Exp Ther 264:1002-1011.
4. 2 High receptors. Eur Neuropsychopharmacol 18:551-556.
5. 3-preferring dopamine agonist. Neurosci Lett 196:97-100.
6. 3 receptor ligands. Bioorg Med Chem 13:77-87.
7. 3 dopaminergic receptor mRNA in the core of the nucleus accumbens accompanies the development of seizures in a genetic model of absence-epilepsy in the rat. Brain Res Mol Brain Res 94:166-177.
8. 3 receptor gene expression and changes in the phenotype of the striatal neurons in mice lacking the dopamine transporter. Eur J Neurosci 12:19-26.
9. 3 receptor function and trafficking by heterodimerization. Mol Pharmacol 74:59-69.
10. Flores G, Wood GK, Barbeau D, Quirion R, Srivastava LK. 1998. Lewis and Fischer rats: A comparison of dopamine transporter and receptors levels. Brain Res 814:34-40.
11. 3 receptors in rat brain. Eur J Pharmacol 211:189-194.
12. George SR, Watanabe M, Di Paolo T, Falardeau P, Labrie F, Seeman P. 1985. The functional state of the dopamine receptor in the anterior pituitary is in the high affinity form. Endocrinology 117:690-697.
13. 2 receptors in vivo using positron emission tomography. J Neurochem 97:1089-1103.
14. 3 receptors. Eur J Pharmacol 272: R1-R3.
15. 11C]-(1)-PHNO PET study. Neuropsychopharmacology 34: 1078-1086.
16. Hill AV. 1910. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. J Physiol (Lond) 40:iv-vii.
17. 3H]R(1)-7- OHDPAT binding in the rat caudate-putamen. Neurochem Int 38: 31-42.
18. 3H]PD 128907 in the caudate-putamen of the adult rat. Brain Res 822:126-131.
19. 2 receptor bands in normal human temporal cortex are absent in Alzheimer's disease. Brain Res 784:7-17.
20. 3 receptor. BMC Biol 2:22.
21. 3 agonist 7-OH-DPAT (7-hydroxy- dipropylaminotetralin) and antipsychotic drugs measured ex vivo by quantitative autoradiography. Can J Physiol Pharmacol 78:7-11.
22. 2High receptors in rats reared in social isolation. Synapse 63:476-483.
23. Leff P. 1995. The two-state model of receptor activation. Trends Pharmacol Sci 16:89-97.
24. 3 dopamine receptors in the brains of several mammalian species. Brain Res 800:269-274.
25. 3 dopamine receptors in rat brain and pituitary gland: A quantitative autoradiographic study. J Pharmacol Exp Ther 264:991-1001.
26. 3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-npropyl-2-aminotetralin. Proc Natl Acad Sci USA 89:8155-8159.
27. Luedtke RR, Mach RH. 2003. Progress in developing D3 dopamine receptor ligands as potential therapeutic agents for neurological and neuropsychiatric disorders. Curr Pharm Des 9: 643-671. (Pubitemid 36221729)
28. 2-like dopamine receptors. Synapse 38:438-449.
29. Martinez D, Narendran R, Foltin RW, Slifstein M, Hwang DR, Broft A, Huang Y, Cooper TB, Fischman MW, Kleber HD, Laruelle M. 2007. Amphetamine-induced dopamine release: Markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine. Am J Psychiatry 164:622-629. (Pubitemid 46650194)
30. 3 receptor interactions in the striatum. J Biol Chem 283:26016-26025.
31. McGonigle P, Molinoff PB. 1989. Quantitative aspects of drug-receptor interactions. In: Siegel GJ, Agranoff BW, Albers RW, Molinoff PB, eds. Basic Neurochemistry. New York, New York: Raven Press; 183-202.
32. 3 receptors gene polymorphisms and neuroleptic malignant syndrome. Am J Med Genet B Neuropsychiatr Genet 117B:57-60.
33. 11C-ZYY-339 in rodents and imaging in non-human primates by PET. Synapse 54:83-91.
34. 3 receptor preferring agonist in vivo. Synapse 60: 485-495.
35. 3 receptor binding in rats receiving a cocaine challenge at various time points after cocaine self-administration: Implications for cocaine-seeking behavior. Neuropsychopharmacology 29:1479-1487.
36. Neve KA, Seamans JK, Trantham-Davidson H. 2004. Dopamine receptor signaling. J Recept Signal Transduct Res 24:165-205.
37. Quik M, Police S, He L, Di Monte DA, Langston JW. 2000. Expression of D3 receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: Effect of levodopa treatment. Neuroscience 98:263-273. (Pubitemid 30347288)
38. 2 components of ex vivo regional (+)-PHNO brain binding in wild-type and knock-out mice. J Nucl Med Meeting Abstracts 48:113P-b.
39. 3 receptor binding potential of (+)-PHNO: Studies in non-human primates and transgenic mice. Synapse 63:782-793.
40. 2 receptor is elevated in the striatum of Parkinson's disease. Mov Disord 13:788-797.
41. Scatchard G. 1949. The attractions of proteins for small molecules and ions. Ann NY Acad Sci 51:662-672.
42. 3 receptor coexistence. Brain Res Brain Res Rev 26:236-242.
43. 2 dopamine receptor. J Biol Chem 257: 6351-6361.
44. Silvers JM, Wallace DR, Harrod SB, Mactutus CF, Booze RM. 2006. Prenatal cocaine alters dopamine and sigma receptor binding in nucleus accumbens and striatum in dams and adolescent offspring. Neurotoxicol Teratol 28:173-180.
45. 3 dopamine receptors. Synapse 63:462-475.
46. 3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J Neurosci 16:6100-6106.
47. 3 receptors on dopaminergic and nondopaminergic cell bodies and terminals. J Pharmacol Exp Ther 295: 1223-1231.
48. Sweet RA, Hamilton RL, Healy MT, Wisniewski SR, Henteleff R, Pollock BG, Lewis DA, DeKosky ST. 2001. Alterations of striatal dopamine receptor binding in Alzheimer disease are associated with Lewy body pathology and antemortem psychosis. Arch Neurol 58:466-472.
49. 18F]F-PHNO. Nucl Med Biol 34:195-203.
50. 3 receptor regulation during expression of and recovery from MPTP-induced parkinsonism. Brain Res 905:111-119.
51. 3 and sigma receptors in the rat striatum and nucleus accumbens using (+/-)-7-hydroxy-N,N- di-n-[3H]propyl-2-aminotetralin and carbetapentane. J Neurochem 64:700-710.
52. 3 receptors. I. In vitro characterization. Synapse 63: 717-728.
53. 3) receptor sites in rat brain. Life Sci 79:772-776.